Sign In
Buy DSNKY
$16.12
-1.81 (-10.09%)
At Close: Jul 31, 2026
Incoming Daiichi Sankyo CEO shares business roadmap going forward
02:30am, Monday, 03'rd Feb 2025
Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with AstraZene
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
10:21pm, Friday, 31'st Jan 2025
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Koji Ogawa -
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
11:05pm, Thursday, 30'th Jan 2025
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. M
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
11:00am, Monday, 13'th Jan 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumo
Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript
01:40pm, Friday, 01'st Nov 2024
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET Company Participants Hiroyuki Okuzawa - Representative Director, President & Chief Operating
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
07:00am, Wednesday, 18'th Sep 2024
Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2-positi
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
06:11am, Tuesday, 17'th Sep 2024
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease
11:00am, Saturday, 31'st Aug 2024
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining
Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript
04:31pm, Monday, 05'th Aug 2024
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global Corpo
Daiichi Sankyo Opens New Affiliate for Oncology in Greece
06:06am, Wednesday, 10'th Jul 2024
ATHENS, Greece--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company's s
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue
03:27am, Wednesday, 12'th Jun 2024
Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the p
RevolKa Signed Master Service Agreement with Daiichi Sankyo
09:00pm, Monday, 27'th May 2024
TOKYO--(BUSINESS WIRE)--RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service ag
Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board
09:03am, Monday, 20'th May 2024
DANBURY, Conn.--(BUSINESS WIRE)--Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today ann
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
12:00am, Monday, 20'th May 2024
AstraZeneca (AZN Quick QuoteAZN - Free Report) announced its plans to spend $1.5 billion to build its first manufacturing facility in Singapore. Once built, it will be the company’s first facility t
Daiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
03:30am, Friday, 26'th Apr 2024
Hiroyuki Okuzawa, president and COO of the Japanese pharma company, discusses the company's results and growth projections.
